Roivant reports preliminary Q3 cash ~$1.5B; VTAMA revenue guided $9.0-9.5M

Roivant Sciences Ltd.

2022-Q3 EPS reported -$1.39 revenue$33,904,000

Cash, cash equivalents and restricted cash ~$1.5B at Dec 31, 2022; pro-forma $1.7B after expected $115M Myovant proceeds.
Net product revenues from VTAMA expected $9.0M to $9.5M for Q3 ending Dec 31, 2022.
Myovant transaction with Sumitomo Pharma expected to close by March 31, 2023.
Preliminary unaudited results; final Q3 2022 financials to be reported in subsequent SEC filing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Roivant Sciences Ltd. reported the third quarter ended December 31, 2022 results: revenue between $9.0 million and $9.5 million.

Period: the third quarter ended December 31, 2022
Revenue: between $9.0 million and $9.5 million
Result: preliminary results

Exact text from the filing

In addition, for the third quarter ended December 31, 2022, the Company expects to report between $9.0 million and $9.5 million in net product revenues from VTAMA. This information is preliminary and unaudited and reflects the Company’s estimated financial results.

View on SEC.gov

Browse all earnings releases →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-23-003906

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.